METAPHARMACEUTICAL IND SL
Josep Plà, 163, 2n 5a / Tel. 933 089 976 / info@metapharmaceutical.com

TECHNICAL DATA SHEET

151306-TDS-ENG-2023

CANNABIDIOL PHARMA (DAC)		
DESCRIPTION DCI: PURE CANNABIDIOL OBTAINED BY CHEMICAL SYNTHESIS		DESCRIPTION DOE: CANNABIDIOL ORIGEN SINTETICO
CAS Nº: 13956-29-1	EC Nº: 689-176-3	AEMPS CODE: 8047OS
MOL. WEIGHT: 314.45	MOL. FORMULA: C21H30O2	ARTICLE CODE: 151306

ATTRIBUTES	SHOULD BE
Appearance	White to pale yellow powder
Identification HPLC	Complies
Identification IR	Complies
Melting point	65.0 - 69.0 ºC
Specific optical rotation	-132.5 / -129.5
Sulfated ash	=< 0.1 %
Water	=< 1.0 %
Related substances	
Olivetol	=< 0.15 %
Olivetol Methylester	=< 0.15 %
(+)-Menthadienol	=< 0.15 %
CBD carboxylic acid methyl ester	=< 0.15 %
CBD hydroxyethyl ester	=< 0.15 %
Unspecified impurities	=< 0.10 %
Total impurities	=< 2.0 %
THC D8 + D9	< 0.05 %
Assay (o.d.b.)	98.0 - 102.0 %
Residual solvents [In-house]	
Diethyleter	=< 5000 ppm
Benzene	=< 2 ppm
Toluene	=< 890 ppm
Ethylene glycol	=< 620 ppm
n-Heptane	=< 5000 ppm
Metals and heavy metals	
Manganese	=< 25 ppm
Arsenic	=< 1.5 ppm
Lead	=< 0.5 ppm
Cadmium	=< 0.2 ppm
Mercury	=< 0.3 ppm
Nickel	=< 2 ppm
Copper	=< 30 ppm
Iron	=< 25 ppm
Cobalt	=< 0.5 ppm
Vanadium	=< 1 ppm
Boron	=< 25 ppm
Tin	=< 25 ppm

TECHNICAL DATA SHEET

151306-TDS-ENG-2023

CANNABIDIOL PHARMA (DAC)		
DESCRIPTION DCI: PURE CANNABIDIOL OBTAINED BY CHEMICAL SYNTHESIS	DESCRIPTION DOE: CANNABIDIOL ORIGEN SINTETICO	
CAS Nº: 13956-29-1	EC Nº: 689-176-3	AEMPS CODE: 8047OS
MOL. WEIGHT: 314.45	MOL. FORMULA: C21H30O2	ARTICLE CODE: 151306

ATTRIBUTES	SHOULD BE
Chromium	=< 25 ppm
Molybdenum	=< 25 ppm
Tungsten	=< 25 ppm

COMPLIES WITH

DAC - Manufacturer Specifications

STORAGE

Keep the container tightly closed. Store it in a dry, dark and cool place.

REMARKS

CANNABIDIOL is subjected to the requirements of the ICH Q3D "Elemental Impurities" guideline.

Certificates of residual solvents, allergens, non-GMO and BSE-TSE are available upon request.

Properties
CANNABIDIOL, also known as CBD is one of the two most important cannabinoid constituents of the cannabis plant, which is found in varying proportions depending on the strain. While in some it is minimal, in others it may be the most abundant, or it may be found in proportions more or less the same as THC.

The most important therapeutic properties of CBD, demonstrated with different quality of evidence are:

Anti-inflammatory
Analgesic
Neuroprotector
Anticonvulsant
Antioxidant
Anti-nausea and antiemetic
Antitumor
Ansiolitic
Antipsychotic
Reducer of appetite for heroin, cocaine and alcohol
Immuno-modulator

These properties make CBD to be used in the treatment of multiple diseases, some of which are:

Epilepsy
Neurodegenerative diseases (for example, Alzheimer's, Parkinson's and Multiple Sclerosis)
Chemical dependencies
Anxiety
Psychosis
Autism spectrum disorder
Chronic inflammatory diseases such as chronic polyarthritis, Crohn's disease, inflammatory bowel disease,
Accompaniment of chemotherapy
Antitumor treatment

Beyond its therapeutic uses, in some jurisdictions, CBD is recommended as a food supplement.

TECHNICAL DATA SHEET

151306-TDS-ENG-2023

CANNABIDIOL PHARMA (DAC)		
DESCRIPTION DCI: PURE CANNABIDIOL OBTAINED BY CHEMICAL SYNTHESIS	DESCRIPTION DOE: CANNABIDIOL ORIGEN SINTETICO	
CAS Nº: 13956-29-1	EC Nº: 689-176-3	AEMPS CODE: 8047OS
MOL. WEIGHT: 314.45	MOL. FORMULA: C21H30O2	ARTICLE CODE: 151306

Adverse effects

Among the adverse effects, generally mild to moderate, when CBD is used in therapeutic doses may be tired, drowsiness, dry mouth, headache, dizziness and decreased appetite. In general they improve with the reduction of the dose of CBD and disappear when the administration is suspended.